AcelRx Pharmaceuticals’ $32.5 Million Acquisition of Lowell Therapeutics

Burns & Levinson LLP represented Lowell Therapeutics, Inc. in its sale to AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, has acquired Lowell Therapeutics. 

With the acquisition of Lowell Therapeutics, AcelRx expands its late-stage development pipeline with Lowell’s lead product, Niyad™, which is an anticoagulant for patients with sudden kidney failure in the ICU who need to go on an artificial kidney machine for dialysis 24/7. Niyad has received Breakthrough Device Designation status from the U.S. FDA and the treatment has been approved in Japan and South Korea as a regional anticoagulant for the dialysis circuit, disseminated intravascular coagulation, and acute pancreatitis.

Lowell Therapeutics, Inc. is focused on the discovery, development and commercialization of innovative therapies intended to significantly improve clinical outcomes in patients. 

The Burns & Levinson deal team was led by partner Gil Breiman (Picture) with significant contributions from Emmanuel Johnson and Rodney Bedow and support from other attorneys at the firm.


Involved fees earner: Rodney Bedow – Burns & Levinson LLP; Gil Breiman – Burns & Levinson LLP; Emmanuel Johnson – Burns & Levinson LLP;

Law Firms: Burns & Levinson LLP;

Clients: Lowell Therapeutics, Inc.;

Sonia Carcano

Author: Sonia Carcano